<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139621">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01999582</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-011-REN-002</org_study_id>
    <secondary_id>2012-003788-23</secondary_id>
    <nct_id>NCT01999582</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Open-Label , Multiple-Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects With End-Stage Kidney Disease on Hemodialysis Switched From Erythropoiesis Stimulating Agents With Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group, Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: To Evaluate the Pharmacokinetics, Safety, Tolerability, Efficacy, Dosing Regimen, and Pharmacodynamics of Sotatercept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the optimal route of administration, dose level, and safety of intravenous and
      subcutaneous dosing of sotatercept for maintaining hemoglobin levels in subjects who are on
      hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum observed concentration in serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Tmax)</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (AUC 28d)</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (t1/2,z)</measure>
    <time_frame>211 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Terminal half life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>211 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>treatment emergent adverse sevents (TEAEs) and number of subjects with TEAEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>113 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in mean hemoglobin concentration between baseline and day 113</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Turnover</measure>
    <time_frame>211 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in serum bone biomarker concentrations between baseline and end of study (day 211)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anemia</condition>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Intravenous Dose Group 1, 2, and 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.3 mg/kg) administered every 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous Dose Group 1, 2, and 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 mg/kg),  administered every14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sotatercept</intervention_name>
    <description>Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.</description>
    <arm_group_label>Intravenous Dose Group 1, 2, and 3</arm_group_label>
    <other_name>ACE-011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sotatercept</intervention_name>
    <description>Sotatercept is dosed subcutaneously every 14 days.  The dose a subject receives will depend on the randomization arm and the dose group.</description>
    <arm_group_label>Subcutaneous Dose Group 1, 2, and 3</arm_group_label>
    <other_name>ACE-011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females ≥ 18 years of age.

          2. Subjects on at least 6 hours of hemodialysis per week, for at least 12 weeks before
             screening

          3. Subjects must be on a stable intravenous or subcutaneous dose of Erythropoietin
             Stimulating Agents (excluding methoxy polyethylene glycol-epoetin beta [Mircera]) to
             maintain hemoglobin.

          4. A mean predialysis hemoglobin concentration ≥ 10 g/dL (grams per deciliter) to ≤ 12
             g/dL (≥ 100 g/L (grams per liter) to ≤ 120 g/L) obtained from three consecutive days.

        4.   A Body Mass Index value ≥ 18.5 kg/m2 (kilograms per m2) at screening. 5.   Understand
        and voluntarily sign an informed consent document prior to       any study related
        assessments/procedures are conducted.

        6.  Able to adhere to the study visit schedule and comply with all protocol requirements.

        Exclusion Criteria:

          1. Non renal causes of anemia

          2. Subjects on peritoneal dialysis.

          3. Systemic hematological disease

          4. Uncontrolled diabetes mellitus (HbA1c (hemoglobin A1c) &gt; 9%) at screening.

          5. Uncontrolled hypertension defined as mean of home systolic blood pressure &gt; 160 mm Hg
             (millimeter of mercury) or mean of home diastolic blood pressure &gt; 90 mm Hg
             calculated once during the screening period prior to randomization

          6. Subjects with heart failure

          7. History of malignancy (except excised and cured non-melanoma skin cancer, or cervical
             carcinoma in situ that was surgically ablated more than 5 years ago).

          8. Anticipated or scheduled living donor renal transplant during the course of the
             study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Smith, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Aversa, BS</last_name>
    <phone>1-732-652-5671</phone>
    <email>daversa@celgene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yemisi Coker, Bsc (Hons)</last_name>
    <phone>+41 32 729 8754</phone>
    <email>ycoker@celgene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier EpiCURA - Clinique Louis Caty de Baudour,</name>
      <address>
        <city>Baudour</city>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg,</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR de la CITADELLE,</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KfH Nierenzentrum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis und Dialysezentrum Karlstraße</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KfH Nierenzentrum</name>
      <address>
        <city>München</city>
        <zip>8084</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KfH Nierenzentrum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nephrocare Faro</name>
      <address>
        <city>Faro</city>
        <zip>8000</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nephrocare Portimão</name>
      <address>
        <city>Portimão</city>
        <zip>8500-311</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Torrecárdenas.</name>
      <address>
        <city>Almeria</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Galdakao-Usansolo</name>
      <address>
        <city>Galdakao</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre, Fundación para la Investigación Biomédica</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Torrevieja</name>
      <address>
        <city>Torrevieja (Alicante)</city>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. George's Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>November 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>End Stage Kidney Disease</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Erythrpoietin Stimulating Agent (ESA)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hematinics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
